Press Releases
-
Advanced BioDesign Strengthens Early Access Program Outcomes, Confirms Steady Progress of ODYSSEY Clinical Trial, and Announces Upcoming Scientific Presentations
Lyon, France – 23rd of March 2026 — Advanced BioDesign, a biotechnology company developing first‑in‑class ALDH1 inhibitors for treatment‑resistant cancers, today released an update on…
-
Advanced BioDesign to Present Groundbreaking Research data on AML at the 67th ASH Annual Meeting
Lyon, France – December 5th, 2025 — Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, is proud to…
-
Media Coverage: Advanced BioDesign Featured in Le Figaro: Accelerating Innovation Against Resistant Cancers
Advanced BioDesign is honored to be featured in Le Figaro Économie, which highlights our cutting-edge approach to overcoming cancer resistance through targeted inhibition of ALDH1—a…
-
Advanced BioDesign Announces Publication in HemaSphere Uncovering Novel Mechanism Driving Chemoresistance in Acute Myeloid Leukemia
Lyon, France – November 6th, 2025 – Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, today announced the…
Advanced BioDesign 